Journey in reverse: TTP from bedside to blood bank to bench.
Thrombotic thrombocytopenic purpura (TTP) is the most extensive and dangerous intravascular platelet clumping disorder. For more than a half-century after its initial recognition, mortality was near 100% and the etiology totally obscure. Then, in the late 1970s to early 1980s, empiric, but successful, therapy by a few clinician/blood bank partnerships was followed by sudden laboratory insight into pathophysiology. The discussion that follows was prepared in conjunction with the 2006 Francis Morrison, M.D., Memorial Lecture at the 27th Annual Meeting of the American Society for Apheresis.
Moake
Joel L
JL
Baylor College of Medicine and Rice University, Houston, Texas 77005, USA. jmoake@rice.edu
D051722:ADAM Proteins / Q000378:metabolism; D000071120:ADAMTS13 Protein; D035843:Biomedical Research / Q000266:history; D000094902:Blood Banking / Q000379:methods; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D011697:Purpura, Thrombotic Thrombocytopenic / Q000209:etiology* / Q000266:history* / Q000628:therapy; D014841:von Willebrand Factor / Q000378:metabolism
D014841:von Willebrand Factor; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human